ACAD Q4 2017 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+264.2% YoY

Gross Profit

$40M91.5% margin

Operating Income

-$70M-160.7% margin

Net Income

-$69M-158.1% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+22.4%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$385M

Total Liabilities

$49M

Stockholders' Equity

$335M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$12M	+264.2%
Gross Profit	$40M	$10M	+313.0%
Operating Income	-$70M	-$78M	+10.5%
Net Income	-$69M	-$79M	+12.5%